Effects of the cardiac myosin activator Omecamtiv-mecarbil on severe chronic aortic regurgitation in Wistar rats
Sign Up to like & getrecommendations! Published in 2018 at "BMC Cardiovascular Disorders"
DOI: 10.1186/s12872-018-0831-3
Abstract: BackgroundAortic regurgitation (AR) is a valvular disease that can lead to systolic heart failure. Treatment options besides cardiac surgery are limited and consequently severe AR is associated with higher mortality and morbidity when not operated.… read more here.
Keywords: activator omecamtiv; omecamtiv mecarbil; myosin activator; cardiac myosin ... See more keywords
The Novel Cardiac Myosin Activator Danicamtiv Improves Cardiac Systolic Function at the Expense of Diastolic Dysfunction In Vitro and In Vivo: Implications for Clinical Applications
Sign Up to like & getrecommendations! Published in 2022 at "International Journal of Molecular Sciences"
DOI: 10.3390/ijms24010446
Abstract: Recent cardiotropic drug developments have focused on cardiac myofilaments. Danicamtiv, the second direct myosin activator, has achieved encouraging results in preclinical and clinical studies, thus implicating its potential applicability in the treatment of heart failure… read more here.
Keywords: cardiac systolic; myosin activator; diastolic dysfunction; danicamtiv improves ... See more keywords